Comparative Pharmacology
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus KLONOPIN RAPIDLY DISINTEGRATING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORDIAZEPOXIDE HYDROCHLORIDE versus KLONOPIN RAPIDLY DISINTEGRATING.
CHLORDIAZEPOXIDE HYDROCHLORIDE vs KLONOPIN RAPIDLY DISINTEGRATING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to benzodiazepine site on GABA-A receptor, enhancing GABA-mediated chloride ion influx, leading to neuronal hyperpolarization and reduced excitability.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Oral: 5-25 mg 3-4 times daily, up to 100 mg/day in severe anxiety; IM/IV: 50-100 mg initially, then 25-50 mg 3-4 times daily.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
None Documented
None Documented
Terminal elimination half-life: 6.6 to 28 hours (parent drug); clinically, duration of effect may be prolonged due to active metabolite nordazepam (half-life 30-100 hours), especially in elderly or hepatic impairment.
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Renal: approximately 50-60% as metabolites (mainly conjugated forms), with less than 1% unchanged. Fecal: minor, about 10%. Biliary excretion contributes to enterohepatic circulation.
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine